Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2021 16:05 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
February 24, 2021 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1...
February 23, 2021 10:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

HIGH POINT, N.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
February 17, 2021 16:05 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara...
January 06, 2021 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually

HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
December 15, 2020 18:15 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type...
December 15, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio

HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for...
November 24, 2020 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital

HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47...
November 05, 2020 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update

HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the...
November 04, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study

HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right